Tag Archive: EPA


Student Services Opportunity – RFQ-OH-15-00044

The United States Environmental Protection Agency (EPA), Cincinnati Procurement Operations Division, is pleased to announce a student services contract opportunity for the Ground Water and Ecosystems Restoration Division in the Office of Research and Development (ORD) in Ada, Oklahoma. The EPA is seeking a student or recent graduate to provide support to the Safety Health and Environmental Management Program (SHEMP).

 

Please post this announcement in an area where students will see it. You may forward this email to individual students or recent graduates. Applications must be received by 5:00 PM EST Friday, May 8, 2015.The announcement is attached to this email and it will be available on the following website: www.FedConnect.net – click on Search Public Opportunities and use Reference Number RFQ-OH-15-00044.

 

All applications must be submitted via FedConnect (www.fedconnect.net). Instructions on how to submit applications are contained in the announcement. The process to apply via FedConnect is lengthy, please allow for at least two weeks to complete the registrations.

 

Thank you,

 

 

Lisa Ryle

Cincinnati Procurement Operations Division
U.S. Environmental Protection Agency
Phone: 513-487-2851
Fax: 513-487-2115
Email: ryle.lisa@epa.gov
http://intranet.epa.gov/oamintra/CPOD/

 

Interest in pharmaceuticals and personal care products (PPCPs) in the environment has grown substantially over the past 10 or so years, with about half of the >15,000 known scientific and policy reports published in just the past few years.  PPCPs are increasingly undergoing scrutiny and regulatory control by federal agencies, states, municipalities, and other countries.  For example:

– The US Food and Drug Administration (FDA), US Environmental Protection Agency (EPA), US Department of Interior (DOI), and US Department of Agriculture (USDA) recently initiated an interagency workgroup to improve and sustain federal coordination and collaboration on pharmaceuticals in water.1

– FDA recently began increasing its assessments of the cumulative impacts of prescription drugs in the environment,2 regulating drugs for endocrine disruption potential,3 and evaluating National Environmental Policy Act (NEPA) environmental review processes.4

– EPA has been assessing prescription and over-the-counter (OTC) drugs in the environment5 and developing rules under the Safe Drinking Water Act (SDWA) that include a number of PPCPs.6

But many questions remain regarding a broad range of topics: 7
– Prioritization of PPCPs
– Pathways of exposure
– Antibiotic resistance
– Bioavailability and uptake
– Effects characterization
– Risk management
– Risk and relative risk

And very little literature has been published for the pharmaceutical scientist audience.  Therefore, in partnership with The American Association of Pharmaceutical Scientists (AAPS) Journal, we are seeking articles for a “rolling online” theme issue, Pharmaceuticals and Personal Care Products (PPCPs) in the Environment.8  If you are interested in contributing to this theme issue, please send me a proposal/abstract for review.

Thanks,
Jim Laurenson
Toxicologist/Environmental Officer
Office of Pharmaceutical Science
Center for Drug Evaluation & Research
U.S. Food & Drug Administration
10903 New Hampshire Ave., Bldg. 21, Rm. 1626
Silver Spring, MD  20993
james.laurenson@fda.hhs.gov

References:
1 FDA, et al. 2012. Memorandum of Understanding on Sustainability of Federal Collaboration on Pharmaceuticals in Drinking Water. http://www.fda.gov/aboutfda/partnershipscollaborations/memorandaofunderstandingmous/domesticmous/ucm335474.htm
2 Laurenson JP, Bloom RA, Page S, and Sadrieh N. 2014. Ethinyl Estradiol and Other Human Pharmaceutical Estrogens in the Aquatic
Environment: A Review of Recent Risk Assessment Data. The AAPS Journal. Online January 28, 2014.
3 FDA. 2013. FDA issues proposed rule to determine safety and effectiveness of antibacterial soaps (news release). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm378542.htm
FDA. 2013. Guidance for Industry: Endocrine Disruption Potential of Drugs: Nonclinical Evaluation (Draft). FDA/CDER, Rockville, MD. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm369043.pdf
4 FDA. 2013. Response to Citizen Petition to the FDA Commissioner Under the National Environmental Policy Act and Administrative
Procedure Act Requesting an Amendment to an FDA Rule Regarding Human Drugs and Biologics. Docket No. FDA-2010-P-0377.
5 Kostich MS, Batt AL, and Lazorchak JM. 2014. Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. Environmental Pollution. 184:354-359.
EPA. 2010. Triclosan Facts. http://www.epa.gov/oppsrrd1/REDs/factsheets/triclosan_fs.htm
6 For example, see: EPA. Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for Public Water Systems. 77 Federal
Register 26071; 2012.
7 Boxall ABA, Rudd MA, Brooks BW, Caldwell DJ, Choi K, Hickmann S, et al. 2012. Pharmaceuticals and Personal Care Products in the
Environment: What are the Big Questions? Environ Health Perspect. 120(9):1221-9.
8 See http://www.pharmagateway.net/ListThemedIssues.aspx?JournalID=12248 for current theme issues.